Peer-reviewed veterinary case report
Topical treatment with esafoxolaner, eprinomectin, and praziquantel
By Knaus, Martin et al.·Published in Parasite (Paris, France)·2021·Boehringer Ingelheim Vetmedica GmbH, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against Notoedres cati mange in cats.
- Species:
- cat
Plain-English summary
A group of 14 cats with mange caused by Notoedres cati were treated with a new topical medication called NexGardCombo, which combines three active ingredients. After just one application, none of the treated cats had live mites, showing that the treatment was 100% effective. The cats also showed significant improvement in their skin lesions and overall health, with all signs of mange disappearing by 42 days after treatment. No side effects were reported during the study, making this a safe and effective option for treating this type of mange in cats.
People also search for: cat mange treatment · Notoedres cati symptoms · NexGardCombo for cats · how to treat cat skin problems
Abstract
The therapeutic efficacy against notoedric mange of a topical combination of esafoxolaner, eprinomectin and praziquantel (NexgardCombo, Boehringer Ingelheim) was evaluated in a masked, controlled clinical study including 14 cats with natural or induced Notoedres cati infestation. Cats were allocated randomly to two groups of seven cats each, to be administered either mineral oil (placebo control) or NexGardCombo. Each treatment was administered once as spot-on at 0.12 mL per kg body weight (representing the minimum label dosage of NexGardCombo, i.e. 1.44 mg esafoxolaner, 0.48 mg eprinomectin, and 10.0 mg praziquantel per kg body weight). Live mites were counted in skin scrapings collected within seven days prior to and 14, 27/28, 42 and 56 days after treatment to calculate the percentage efficacy of NexGardCombo based on the comparison of mean live mite counts of the two groups. Concurrently, mange lesions and clinical signs were scored to establish a clinical success valuation. No live mites were recovered from any NexGardCombo-treated cats post-treatment, indicating 100% therapeutic efficacy following a single spot-on administration of the novel antiparasitic combination. The clinical success valuations in the NexGardCombo-treated cats were 14.3%, 42.8%, 100% and 100% at 14, 27/28, 42 and 56 days after treatment, respectively. No health problems were observed throughout the study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33812459/